Gibco™ Human Sclerostin Recombinant Protein, PeproTech®

Catalog No.	Quantity
100-49-20UG	20 μg
10049100UG	100 μg
100-49-1MG	1 mg
10049250UG	250 μg
10049500UG	500 μg
100-49-5UG	5 μg

Catalog No. 100-49-20UG Supplier Gibco™ Supplier No. 1004920UG

Description

Recombinant Protein

PeproTech's CHO cell-derived Recombinant Human Sclerostin is a 190-amino-acid-length glycoprotein with a calculated molecular weight of 21.5 kDa. As a result of glycosylation, Recombinant Human Sclerostin migrates with an apparent molecular mass of approximately 28-35 kDa by SDS-PAGE gel, under non-reducing conditions. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Sclerostin, a glycoprotein predominantly secreted by osteocytes, is a member of the Cerberus/DAN family of putative BMP antagonists that functions as an endogenous regulator of the canonical Wnt signaling pathway and an inhibitory regulator of bone homeostasis. Although expressed nearly exclusively by osteocytes, sclerostin can also be found at significant levels elsewhere, such as bone, bone marrow, cartilage, the kidney, and the liver, and has also been shown to be produced by hypertrophic chondrocytes and cementocytes. Like DKK family members DKK-1 and DKK-4, sclerostin plays an important regulatory role in the Wnt/beta-catenin signaling pathway by forming inhibitory complexes with LDL Receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/beta-catenin signaling system. LRP5 and LRP6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/beta-catenin signaling cascade. Sclerostin has also been shown to interact directly with LRP4 via its extracellular domain to facilitate inhibition of Wnt signaling, and can catabolically promote osteoclast activity by increasing osteocyte expression of RANKL. Sclerostin's critical involvement in the regulation of bone formation and resorption is emphasized by two bone dysplasia disorders, sclerosteosis and van Buchem disease (VBD), caused by rare autosomal recessive mutations that result in progressive bone overgrowth and hypermineralization due to markedly decreased sclerostin levels.

Specifications

• Accession Number: Q9BQB4
• For Use With (Application): Control, Bioactivity
• Formulation: Protein with no preservative
• Gene ID (Entrez): 50964
• Molecular Weight (g/mol): 21.5 kDa
• Name: Human Sclerostin
• Purification Method: Purified
• Quantity: 20 μg
• Source: CHO cells
• Storage Requirements: -20°C
• Regulatory Status: RUO
• Endotoxin Concentration: <1 EU/μg
• Gene Alias: 5430411E23Rik; CDD; DAND6; sclerosteosis; sclerostin; SOST; SOST1; UNQ2976/PRO7455/PRO7476; VBCH
• Common Name: Sclerostin
• Gene Symbol: SOST
• Biological Activity: Determined by its ability to downregulate alkaline phosphatase activity in differentiating MC3T3-E1 cells in the presence of 20 ng/ml murine Wnt-3 a.
• Product Type: Protein
• Conjugate: Unconjugated
• Recombinant: Recombinant
• Sequence: QGWQAFKNDA TEIIPELGEY PEPPPELENN KTMNRAENGG RPPHHPFETK DVSEYSCREL HFTRYVTDGP CRSAKPVTEL VCSGQCGPAR LLPNAIGRGK WWRPSGPDFR CIPDRYRAQR VQLLCPGGEA PRARKVRLVA SCKCKRLTRF HNQSELKDFG TEAARPQKGR KPRPRARSAK ANQAELENAY
• Content And Storage: -20°C
• Activity: Determined by its ability to downregulate alkaline phosphatase activity in differentiating MC3T3-E1 cells in the presence of 20ng/ml murine Wnt-3a.
• Expression System: CHO cells
• Form: Lyophilized
• Purity or Quality Grade: ≥ 95% by SDS-PAGE gel and HPLC analyses.